Twist Bioscience Reports Monday With Breakeven Timeline Now Three Quarters Away

Twist Bioscience (TWST) is set to report fiscal third-quarter earnings, with investors focusing on the company's path to profitability and its role in AI-enabled drug discovery after a significant 154% surge in its stock price over the past year. Analysts have a largely bullish stance with a mean price target of $104, though recent downgrades highlight valuation concerns. The report is expected to show a loss of $0.50 per share on revenues of $114.6 million, and historical data indicates significant price volatility around earnings releases.